We assessed the expression levels of miR-206, miR-133a, miR-133b and miR-1 in serum of mutant-SOD1-ALS, pediatric SMA, and SBMA patients (as illustrated in Table 1), to evaluate the potential of these myomiRs as noninvasive clinical biomarkers in the human pathologies. This evidence concerns the gene SOD1 and proximal spinal muscular atrophy.